- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 1: Formulary Exclusivity Deals
The panelists discuss the evidence that is weighed when determining whether or not to include a particular therapy on their regimens.
The panelists discuss the evidence that is weighed when determining whether or not to include a particular therapy on their regimens.
Cost is a significant factor, admitted Matthew D. Harman, PharmD, MPH, especially since many payers felt burned by the price of Sovaldi the first time around. However, Ed Cohen, PharmD, FAPhA, said Walgreens stays neutral for of its payer clients and adheres to their formulary practices.
Steven Miller, MD, MBA, explained that since Harvoni and Viekira Pak seem to be equivalent in both use and outcome based on the studies, Express Scripts’ independent committee labelled both drugs as optional and let plans choose which one they wanted to add.
“Our national preferred formulary chose Viekira Pak, many of our other clients have chosen Harvoni,” he said. “We are fine with both and we have negotiated really great rates for all of our clients regardless of the products they’ve chosen.”
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
September 27th 2025The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.
Read More
Managed Care Reflections: A Q&A With Dora Hughes, MD, MPH
September 4th 2025To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The September issue features a conversation with Dora Hughes, MD, MPH, chief medical officer and director of the Center for Clinical Standards and Quality at CMS.
Read More
Prevention, Early Intervention Highlighted in Updated High Blood Pressure Guidelines
September 4th 2025A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.
Read More
